ProPhase Labs (NASDAQ:PRPH – Get Free Report) is projected to post its quarterly earnings results before the market opens on Thursday, March 27th. Analysts expect ProPhase Labs to post earnings of ($0.24) per share and revenue of $3.77 million for the quarter.
ProPhase Labs Price Performance
ProPhase Labs stock opened at $0.48 on Wednesday. The firm has a market capitalization of $11.46 million, a price-to-earnings ratio of -0.38 and a beta of -0.53. ProPhase Labs has a 52-week low of $0.22 and a 52-week high of $7.48. The company has a fifty day simple moving average of $0.42 and a 200-day simple moving average of $1.12. The company has a quick ratio of 1.33, a current ratio of 1.47 and a debt-to-equity ratio of 0.48.
Wall Street Analysts Forecast Growth
Separately, StockNews.com initiated coverage on shares of ProPhase Labs in a research report on Tuesday, February 25th. They set a “sell” rating for the company.
About ProPhase Labs
ProPhase Labs, Inc develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.
Read More
- Five stocks we like better than ProPhase Labs
- How to Use the MarketBeat Stock Screener
- Innovation Incubators: Survey of Entrepreneurs Reveals The Cities Most Supportive of Startups
- What is a Special Dividend?
- NVIDIA Insiders Sell: This Is What It Means for the Market
- What is Short Interest? How to Use It
- Space Stocks Bottoming: Which Are Positioned Best for a Bounce?
Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.
